Current Trials

F01424 – RSV mRNA Vaccine Trial

 Fusion Clinical Research, Norwood

RSV is the leading viral agent causing severe respiratory tract disease worldwide in older adults. It is also a common cause of pneumonia and bronchiolitis in small children. There is a medical need to improve patient quality of life by preventing lower respiratory tract disease (LRTD).

This study will evaluate the clinical efficacy of a new RSV mRNA vaccine in people 60+ years of age.

Main Exclusions*:
– Allergic reactions (e.g. anaphylaxis) to mRNA vaccines.
– Known systemic hypersensitivity to vaccines or vaccine components.
– Diagnosed RSV infection in previous 12 months.
– Previous history of myocarditis, pericarditis, and / or myo-pericarditis.
– Received any mRNA vaccine in the last 60 days.
– Received any vaccine in the last 4 weeks or plan to receive any vaccine in the 4 weeks following study vaccine administration.
– Previously been vaccinated against RSV.

* This list is not exhaustive.

TO REGISTER, PLEASE FOLLOW THE LINK AT THE BOTTOM OF THIS PAGE.

Untitled design (8)

Eligibility requirements

  • Age: 60+
  • Sex: Any

Overnight Stays

  • Nil

Outpatient Visits

  • 2-3

Payment/Remuneration

  • $200 for the vaccination visit and $150 for all other on site visits.

How to apply

To register your interest in this trial, please complete this form, or call us on 1800-FUSION (1800 387 466). A Fusion team member will be in contact to discuss your eligibility shortly.